Diagnostic molecular biomarkers for malignant pleural effusions

被引:24
作者
Sriram, Krishna B. [1 ,2 ]
Relan, Vandana [1 ,2 ]
Clarke, Belinda E. [3 ]
Duhig, Edwina E. [3 ]
Yang, Ian A. [1 ,2 ]
Bowman, Rayleen V. [1 ,2 ]
Lee, Y. C. Gary [4 ,5 ,6 ,7 ]
Fong, Kwun M. [1 ,2 ]
机构
[1] Univ Queensland, Thorac Res Ctr, Sch Med, Brisbane, Qld 4072, Australia
[2] Prince Charles Hosp, Dept Thorac Med, Brisbane, Qld, Australia
[3] Prince Charles Hosp, Dept Anat Pathol, Brisbane, Qld, Australia
[4] Univ Western Australia, Sch Med & Pharmacol, Perth, WA 6009, Australia
[5] Univ Western Australia, CAARR, Perth, WA 6009, Australia
[6] Sir Charles Gairdner Hosp, Resp Dept, Perth, WA 6000, Australia
[7] Lung Inst Western Australia, Pleural Dis Unit, Perth, WA, Australia
关键词
biological markers; cytology; DNA copy-number changes; gene expression; malignant pleural effusion; methylation; IN-SITU HYBRIDIZATION; ENDOTHELIAL GROWTH-FACTOR; MEGAKARYOCYTE POTENTIATING FACTOR; COMPARATIVE GENOMIC HYBRIDIZATION; POLYMERASE-CHAIN-REACTION; CELL LUNG-CANCER; GENE-EXPRESSION; DNA METHYLATION; TELOMERASE ACTIVITY; MESSENGER-RNA;
D O I
10.2217/FON.11.45
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Malignant pleural effusions (MPEs) are a common and important cause of cancer-related mortality and morbidity. Prompt diagnosis using minimally invasive tests is important because the median survival after diagnosis is only 4-9 months. Pleural fluid cytology is pivotal to current MPE diagnostic algorithms but has limited sensitivity (30-60%). Consequently, many patients need to undergo invasive diagnostic tests such as thoracoscopic pleural biopsy. Recent genomic, transcriptomic, methylation and proteomic studies on cells within pleural effusions have identified novel molecular diagnostic biomarkers that demonstrate potential in complementing cytology in the diagnosis of MPEs. Several challenges will need to be addressed prior to the incorporation of these molecular tests into routine clinical diagnosis, including validation of molecular diagnostic markers in well-designed prospective, comparative and cost-effectiveness studies. Ultimately, minimally invasive diagnostic tests that can be performed quickly will enable clinicians to provide the most effective therapies for patients with MPEs in a timely fashion.
引用
收藏
页码:737 / 752
页数:16
相关论文
共 159 条
  • [1] A Prospective Study of the Volume of Pleural Fluid Required for Accurate Diagnosis of Malignant Pleural Effusion
    Abouzgheib, Wissam
    Bartter, Thaddeus
    Dagher, Hikmat
    Pratter, Melvin
    Klump, William
    [J]. CHEST, 2009, 135 (04) : 999 - 1001
  • [2] Caveolin-1 is a novel immunohistochemical marker to differentiate epithelioid mesothelioma from lung adenocarcinoma
    Amatya, Vishwa Jeet
    Takeshima, Yukio
    Kohno, Hidekazu
    Kushitani, Kei
    Yamada, Taketo
    Morimoto, Chikao
    Inai, Kouki
    [J]. HISTOPATHOLOGY, 2009, 55 (01) : 10 - 19
  • [3] Aoe K, 2006, ANTICANCER RES, V26, P4833
  • [4] The management of malignant pleural mesothelioma; single centre experience in 10 years
    Aziz, T
    Jilaihawi, A
    Prakash, D
    [J]. EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2002, 22 (02) : 298 - 305
  • [5] MicroRNAs: Novel Biomarkers for Human Cancer
    Bartels, Claudine L.
    Tsongalis, Gregory J.
    [J]. CLINICAL CHEMISTRY, 2009, 55 (04) : 623 - 631
  • [6] Benjamin H, 2008, J CLIN ONCOL S15, V26
  • [7] A Diagnostic Assay Based on MicroRNA Expression Accurately Identifies Malignant Pleural Mesothelioma
    Benjamin, Hila
    Lebanony, Danit
    Rosenwald, Shai
    Cohen, Lahav
    Gibori, Hadas
    Barabash, Naama
    Ashkenazi, Karin
    Goren, Eran
    Meiri, Eti
    Morgenstern, Sara
    Perelman, Marina
    Barshack, Iris
    Goren, Yaron
    Edmonston, Tina Bocker
    Chajut, Ayelet
    Aharonov, Ranit
    Bentwich, Zvi
    Rosenfeld, Nitzan
    Cohen, Dalia
    [J]. JOURNAL OF MOLECULAR DIAGNOSTICS, 2010, 12 (06) : 771 - 779
  • [8] Potential diagnostic value of methylation profile in pleural fluid and serum from cancer patients with pleural effusion
    Benlloch, Susana
    Galbis-Caravajal, Jose Marcelo
    Martin, Concepcion
    Sanchez-Paya, Jose
    Rodriguez-Paniagua, Jose Manuel
    Romero, Santiago
    Mafe, Juan Jose
    Massuti, Bartomeu
    [J]. CANCER, 2006, 107 (08) : 1859 - 1865
  • [9] HIGH-FREQUENCY OF INACTIVATING MUTATIONS IN THE NEUROFIBROMATOSIS TYPE-2 GENE (NF2) IN PRIMARY MALIGNANT MESOTHELIOMAS
    BIANCHI, AB
    MITSUNAGA, SI
    CHENG, JQ
    KLEIN, WM
    JHANWAR, SC
    SEIZINGER, B
    KLEY, N
    KLEINSZANTO, AJP
    TESTA, JR
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (24) : 10854 - 10858
  • [10] Braunschweig R, 2001, DIAGN CYTOPATHOL, V24, P174, DOI 10.1002/1097-0339(200103)24:3<174::AID-DC1036>3.3.CO